LISPRO-PH20 COMPONENT RHUPH20

Hereditary Angioedema

Shireprotein_peptidePhase 2Dormant

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 47/ 100
Competitive Position: 89/ 100

Competitive context

17 Active assets in the Hereditary Angioedema cohort.

Asset / Sponsor	Phase	Rating
Firazyr Nang Kuang Pharmaceutical Co., Ltd.	Phase 4	A
Sebetralstat KalVista Pharmaceuticals, Ltd.	Phase 4	A
Firazyr Nang Kuang Pharmaceutical Co., Ltd.	Phase 4	A
Berotralstat BioCryst Pharmaceuticals	Phase 3	A
Lanadelumab Takeda	Phase 3	A

View all 37 →

Same molecule, other indications

LISPRO-PH20 COMPONENT RHUPH20 is also rated in:

smoldering plasma cell myelomaDormant

B

Indicative ·

59 / 100

melanomaDormant

B

Indicative ·

56 / 100

plasma cell myelomaDormant

CCC

Indicative ·

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.